The Iraqi Board for Medical Specializations
  • Register
  • Login

Iraqi Postgraduate Medical Journal

Notice

As part of Open Journals’ initiatives, we create website for scholarly open access journals. If you are responsible for this journal and would like to know more about how to use the editorial system, please visit our website at https://ejournalplus.com or
send us an email to info@ejournalplus.com

We will contact you soon

  1. Home
  2. Volume 21, Issue 3
  3. Authors

Current Issue

By Issue

By Subject

Keyword Index

Author Index

Indexing Databases XML

About Journal

Aims and Scope

Editorial Board

Advisory Board

Editorial Staff

Publication Ethics

Indexing and Abstracting

News

Transdermal Scopolamine Alternative to Ondansetron for Prevention of Early 6 Hours Postoperative Laparoscopic Cholecystectomy Emetic Symptoms

    Raghad Hannon Alsudani Asmaa Khalid Al- Hayali

Iraqi Postgraduate Medical Journal, 2022, Volume 21, Issue 3, Pages 306-310
10.52573/ipmj.2021.175793

  • Show Article
  • References
  • Download
  • Cite
  • Statistics
  • Share

Abstract

BACKGROUND:
Nausea and vomiting are the commonest complication Post-operatively which are usually                         self-limiting; however, it can cause serious consequences. There are many drugs to manage                       Post-operative nausea and vomiting.
OBJECTIVE:
Compare the efficacy of transdermal scopolamine versus ondansetron for the prevention of                         post-operative laparoscopic cholecystectomy emetic symptoms.
PATIENTS AND METHODS:
One hundred patients who were candidate for undergoing laparoscopic cholecystectomy are divided in to two groups each of them have 50 patients, first group received an active TDS patch  (containing scopolamine 1.5 mg) 60 min before entering the operating room. The second group was administered ondansetron, 4 mg that was administered I.V near the end of the procedure, and all patients received                a standardized general anesthetic technique.
RESULTS:
There were no significant differences in any of the emetic outcomes orneed for rescue antiemetics between TDS and ondansetron groups inthe first 6 h after surgery.
CONCLUSION:
Premedication with TDS (1.5) mg was as effective as ondansetron (4 mg) in preventing nausea and vomiting in the early postoperative periods. Also less cost with TDS patch.
 
Keywords:
    transdermal scopolamine ondansetron nausea and vomiting, antiemetic
  • PDF (183 K)
  • XML
(2021). Transdermal Scopolamine Alternative to Ondansetron for Prevention of Early 6 Hours Postoperative Laparoscopic Cholecystectomy Emetic Symptoms. Iraqi Postgraduate Medical Journal, 21(3), 306-310. doi: 10.52573/ipmj.2021.175793
Raghad Hannon Alsudani; Asmaa Khalid Al- Hayali. "Transdermal Scopolamine Alternative to Ondansetron for Prevention of Early 6 Hours Postoperative Laparoscopic Cholecystectomy Emetic Symptoms". Iraqi Postgraduate Medical Journal, 21, 3, 2021, 306-310. doi: 10.52573/ipmj.2021.175793
(2021). 'Transdermal Scopolamine Alternative to Ondansetron for Prevention of Early 6 Hours Postoperative Laparoscopic Cholecystectomy Emetic Symptoms', Iraqi Postgraduate Medical Journal, 21(3), pp. 306-310. doi: 10.52573/ipmj.2021.175793
Transdermal Scopolamine Alternative to Ondansetron for Prevention of Early 6 Hours Postoperative Laparoscopic Cholecystectomy Emetic Symptoms. Iraqi Postgraduate Medical Journal, 2021; 21(3): 306-310. doi: 10.52573/ipmj.2021.175793
  • RIS
  • EndNote
  • BibTeX
  • APA
  • MLA
  • Harvard
  • Vancouver

  1. White PF, Watcha MF. Postoperative nausea and vomiting: prophylaxis versus treatment. Anesth Analg 2015; 89:1337–39.
  2. Pierre S. Risk scores for predicting postoperative nausea and vomiting are clinically useful tools and should be used in every patient:. European Journal of Anesthesiology (EJA). 2011 Mar 1;28:160-63.
  3. Sweeney BP. Why does smoking protect against post-operative nausea and vomiting? Br J Anaesth 2016;89: 810-13
  4. Sébastien Pierre, Rachel Whelan; Nausea and vomiting after surgery, Continuing Education in Anesthesia Critical Care & Pain, Volume 13, Issue 1, 1 February 2013:28–32.
  5. Apfel CC, Kranke P, Katz MH, et al .Volatile anaesthetics may be the main cause of early but not delayed postoperative vomiting: a randomized controlled trial of factorial design. British Journal of Anaesthesia. 2015; 88:659-68.
  6. Kothari SN, Boyd WC, Bottcher ML, et al. Antiemetic efficacy of prophylactic dimenhydrinate (Dramamine) vs ondansetron (Zofran). Surgical endoscopy. 2000;14:926-29.
  7. Tramer MR, Reynolds DJ, Moore RA, et al. Efficacy, Dose-Response, and Safety of Ondansetron in Prevention of Postoperative Nausea and Vomiting A Quantitative Systematic Review of Randomized Placebo-controlled Trials. Anesthesiology: The Journal of the American Society of Anesthesiologists. 2017;87:1277-89.
  8. Cronin CM, Sallan SE, Wolfe L. Transdermal scopolamine in motion sickness. Pharmacotherapy 1982;2:29–31.
  9. Kranke P, Morin AM, Roewer N, et al. The efficacy and safety of transdermal scopolamine for the prevention of postoperative nausea and vomiting: a quantitative systematic review. AnesthAnalg 2002;95:133–43.

10. Tarkkila P, Torn K, Tuominen M, Lindgren L. Premedication with promethazine and transdermal scopolamine reduces the Incidence of nausea and vomiting after intrathecal morphine. Acta Anaesthesiol Scand 2015;39:983–6.

11. Pergolizzi Jr JV, Philip BK, Leslie JB, Taylor Jr R,et al Perspectives on transdermal scopolamine for the treatment of postoperative nausea and vomiting. Journal of clinical anesthesia. 2012;24:334-45.

12. Apfel CC, Zhang K, George E,et al. Transdermal scopolamine for the prevention of postoperative nausea and vomiting: a systematic review and meta-analysis. Clinical therapeutics. 2010 ;32:1987-2002.

13. Sah N, Ramesh V, Kaul B, Dalby P, Shestak K, et al Transdermal scopolamine patch in addition to ondansetron for postoperative nausea and vomiting prophylaxis in patients undergoing ambulatory cosmetic surgery. Journal of clinical anesthesia. 2009;21:249-52.

  • Article View: 46
  • PDF Download: 15
  • LinkedIn
  • Twitter
  • Facebook
  • Google
  • Telegram
  • Home
  • Glossary
  • News
  • Aims and Scope
  • Privacy Policy
  • Sitemap
This journal is licensed under a Creative Commons Attribution 4.0 International (CC-BY 4.0)

Powered by eJournalPlus